Larynx carcinoma regulates tumor-associated macrophages through PLGF signaling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhou, Xu ^a   Qi, Ying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MMP3 PROTEIN, HUMAN; MMP3 PROTEIN, MOUSE; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, MOUSE; PGF PROTEIN, HUMAN; PGF PROTEIN, MOUSE; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN;

ANIMAL; FEMALE; HUMAN; LARYNX TUMOR; MACROPHAGE; MALE; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MACROPHAGES; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM PROTEINS; PLACENTA GROWTH FACTOR; PREGNANCY PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929224674     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10071     Document Type: Article

References (38)

1. Mojica-Manosa, P., Reidy, J., Wilson, K. & Douglas, W. Larynx squamous cell carcinoma: concepts and future directions. Surg. Oncol. Clin. N. Am. 13, 99-112, doi:10.1016/S1055-3207(03)00130-3 (2004).
2. Sion-Vardy, N., Fliss, D. M., Prinsloo, I., Shoham-Vardi, I. & Benharroch, D. Neoangiogenesis in squamous cell carcinoma of the larynx - biological and prognostic associations. Pathol. Res. Pract. 197, 1-5 (2001).
3. Sullu, Y., Gun, S., Atmaca, S., Karagoz, F. & Kandemir, B. Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx. Diagn. Pathol. 5, 35, doi:10.1186/1746-1596- 5-35 (2010).
4. Melinceanu, L. et al. Serum perioperative profile of cytokines in patients with squamous cell carcinoma of the larynx. Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 40, 143-s150 (2011).
5. Dufour, A. & Overall, C. M. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34, 233-242, doi:10.1016/j.tips.2013.02.004 (2013).
6. Davidson, B., Reich, R., Risberg, B. & Nesland, J. M. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh. Patol. 64, 47-53 (2002).
7. Rhee, J. S. & Coussens, L. M. RECKing MMP function: implications for cancer development. Trends Cell Biol. 12, 209-211 (2002).
8. Xia, Q., Li, C., Bian, P., Wang, J. & Dong, S. Targeting SMAD3 for inhibiting prostate cancer metastasis. Tumour Biol. 35, 8537-8541, doi:10.1007/s13277-014-2368-0 (2014).
9. Wang, F., Xiao, W., Sun, J., Han, D. & Zhu, Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 35, 8653-8658, doi:10.1007/s13277-014-2131-6 (2014).
10. Song, H. et al. Astrocyte elevated gene-1 activates MMP9 to increase invasiveness of colorectal cancer. Tumour Biol. 35, 6679- 6685, doi:10.1007/s13277-014-1883-3 (2014).
11. Pei, J., Lou, Y., Zhong, R. & Han, B. MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 35, 6673-6678, doi:10.1007/s13277-014-1850-z (2014).
12. Chen, J., Huang, Q. & Wang, F. Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma. Tumour Biol. 35, 7195-7200, doi:10.1007/s13277-014-1913-1 (2014).
13. Colovic, Z. et al. Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx. Collegium antropologicum 37, 151-155 (2013).
14. Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200, doi:10.1172/JCI70212 (2013).
15. Yang, Y., Sun, M., Wang, L. & Jiao, B. HIFs, angiogenesis, and cancer. J. Cell Biochem. 114, 967-974, doi:10.1002/jcb.24438 (2013).
16. Ferrara, N. Vascular endothelial growth factor. Arterioscler Thromb. Vasc. Biol. 29, 789-791, doi:ATVBAHA.108.179663 (2009).
17. Xiao, X. et al. Pancreatic duct cells as a source of VEGF in mice. Diabetologia 57, 991-1000, doi:10.1007/s00125-014-3179-y (2014).
18. Xiao, X. et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic Beta cells as a regulator of Beta cell mass. J. Biol. Chem. 288, 8636-8646, doi:10.1074/jbc.M112.422949 (2013).
19. Eichmann, A. & Simons, M. VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 24, 188-193, doi:S0955-0674(12)00015-4 (2012).
20. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307, doi:nature10144 (2011).
21. Ferrara, N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr. Opin. Hematol. 17, 219-224, doi:10.1097/MOH.0b013e3283386660 (2010).
22. Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21, 21-26, doi:S1359-6101(09)00110-5 (2010).
23. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575-583, doi:10.1038/87904 (2001).
24. Eriksson, A. et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1, 99-108 (2002).
25. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10, 554-567, doi:10.1038/nri2808 (2010).
26. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964, doi:10.1038/nri1733 (2005).
27. Pollard, J. W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 9, 259-270, doi:10.1038/nri2528 (2009).
28. Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175-189, doi:10.1016/j.cell.2005.10.036 (2006).
29. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237, doi:S0952-7915(10)00010-5 (2010).
30. Xiao, X. et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc. Natl. Acad. Sci. U S A 111, E1211-1220, doi:10.1073/pnas.1321347111 (2014).
31. Zhou, X. & Qi, Y. PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation. Tumour Biol. 35, 9381-9386, doi:10.1007/s13277-014-2232-2 (2014).
32. Nanda, G. S., Sun, F. X., Hofmann, G. A., Hoffman, R. M. & Dev, S. B. Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res. 18, 999-1004 (1998).
33. Dev, S. B. et al. Magnetic resonance studies of laryngeal tumors implanted in nude mice: effect of treatment with bleomycin and electroporation. Magnetic resonance imaging 20, 389-394 (2002).
34. Song, X., Xie, S., Lu, K. & Wang, C. Mesenchymal Stem Cells Alleviate Experimental Asthma by Inducing Polarization of Alveolar Macrophages. Inflammation, doi:10.1007/s10753-014-9954-6 (2014).
35. Shen, B., Liu, X., Fan, Y. & Qiu, J. Macrophages Regulate Renal Fibrosis Through Modulating TGFbeta Superfamily Signaling. Inflammation, doi:10.1007/s10753-014-9941-y (2014).
36. Matsuyama, S. et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 63, 7791-7798 (2003).
37. Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (2002).
38. McKay, M. M. & Morrison, D. K. Integrating signals from RTKs to ERK/MAPK. Oncogene 26, 3113-3121, doi:10.1038/sj. onc.1210394 (2007).